This test includes a urine drug screen by immunoassay and a confirmation by liquid-chromatography time-of-flight high resolution mass spectrometry. This test has the capability to qualitatively confirm all major classes of drugs including opioids, amphetamines (including methylphenidate), cocaine, benzodiazepines, oxycodone, cannabinoids (THC), methadone, buprenorphine (Suboxone). Metabolites (when observed) of all opioids (for example: noroxycodone presence confirms oxycodone use) are also reported. The test includes extended opioids and benzodiazepines including hydrocodone, buprenorphine, hydromorphone, tramadol, tapentadol, fentanyl, lorazepam, clonazepam, anti-depressants, anti-psychotics, commonly abused OTC drugs and other drugs like gabapentin, pregabalin (Lyrica). Novel designer drugs including bath salts , designer stimulants and fentanyl analogs can be identified by this method.
UDSC Confirmatory testing is recommended for patients who are:
Co-prescribed opioids (especially hydrocodone) and bensodiazepines
Monitored for lorazepam and/or clonazepam
Monitored for fentanyl
Present as a high risk for diversion
Have a previous history of drug overdose
Have a previous history of designer drug use
A medication list review is performed and an interpretive report showing concordance (or discordance) from the listed medications will be provided in the result report. Drugs that are qualitatively confirmed will be reported under specific drug classes.
A list of approximately 250 drugs included in the testing l8ibrary can be provided upon request.
The Toxicology and Drug Analysis Laboratory can be contacted at 734-936-6758 between 7am - 11pm..